Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras

NCT00972465 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT00972465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00972465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study of Nimotuzumab Plus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer With Wild Type K-ras
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2009
Completion date
April 30, 2010
Enrollment
48 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer